Ebola Virus Disease in Mice with Transplanted Human Hematopoietic Stem Cells

Anja Lüdtke, Lisa Oestereich, Paula Ruibal, Stephanie Wurr, Elisa Pallasch, Sabrina Bockholt, Wing Hang Ip, Toni Rieger, Sergio Gómez-Medina, Carol Stocking, Estefanía Rodriguez, Stephan Günther, César Muñoz-Fontela

Heinrich Pette Institute, Leibniz Institute for Experimental Virology, Hamburg, Germany; Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany; German Centre for Infection Research (DZIF), Partner Site Hamburg, Hamburg, Germany

The development of treatments for Ebola virus disease (EVD) has been hampered by the lack of small-animal models that mimick human disease. Here we show that mice with transplanted human hematopoietic stem cells reproduce features typical of EVD. Infection with Ebola virus was associated with viremia, cell damage, liver steatosis, signs of hemorrhage, and high lethality. Our study provides a small-animal model with human components for the development of EVD therapies.

Ebola virus disease (EVD) is a highly lethal viral syndrome characterized by fever, viremia, multiorgan failure, and, in some cases, bleeding (1). The magnitude of the current EVD outbreak in West Africa has highlighted the need for specific medical countermeasures against EVD (2), but the lack of small-animal models of disease has precluded preclinical testing of therapies. Inbred laboratory mice are resistant to infection with nonadapted Ebola virus (EBOV) and are susceptible only to mouse-adapted EBOV (maEBOV) injected intraperitoneally (i.p.) (3, 4). However, maEBOV infection does not reproduce human EVD pathogenesis unless mouse genetic diversity is increased via systematic crossing of inbred strains (5). Alternatively, mice with deficient innate immunity, such as type I interferon receptor knockout (IFNAR−/−) or STAT-1 knockout, are susceptible to both EBOV and maEBOV by several routes, but these mice cannot serve to translate basic findings to human disease due to the lack of a competent immune system (3). In this study, we sought to develop a small-animal model with human hematopoietic cells susceptible to nonadapted EBOV.

Severely immunodeficient mice, such as nonobese diabetic (NOD)/severe combined immunodeficiency (scid)/interleukin-2 receptor-γ chain knockout (NSG) mice, allow long-term engraftment of human tissues due to the lack of mature T and B cells (6). In addition, NSG mice are deficient for several high-affinity receptors for cytokines, including IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21, that block the development of natural killer (NK) cells and further impair host innate immunity (6, 7). Previous studies have demonstrated the suitability of NSG mice as a small-animal model for human viral infections, including infections with HIV, Epstein-Barr virus (EBV), influenza virus, and dengue virus (8–11).

To reconstitute the human hematopoietic system in NSG-A2 mice, we utilized the NOD.Cg-Prkdcscid/Il2rgm1Wjl Tg (HLA-A2.1) 1Enge/SzJ mouse strain from Jackson Laboratories. These mice were kept in individually ventilated cages inside the biosafety level 4 (BSL4) laboratory at the Bernhard Nocht Institute in Hamburg, Germany, and fed with autoclaved food and water. Human CD34+ hematopoietic stem cells (HSCs) were purified from umbilical cord blood of HLA-A2+ donors using a Ficoll gradient and subsequent positive antibody selection (StemSep human CD34 positive selection cocktail; Stem Cell Technologies). All patients agreed to donation of biological material by informed written consent under a protocol approved by the local ethics committee, and all animal experiments were conducted according to the guidelines of the German animal protection law. Four- to 5-week-old female mice were conditioned by sublethal irradiation (240 cGy), and 3 to 4 h later, we transplanted 10⁶HSCs/mouse via intravenous injection (retro-orbital). Eight to 12 weeks posttransplantation, peripheral blood, spleen, and bone marrow samples were tested for the presence of human hematopoietic cells using the panleukocyte marker CD45. All organs and blood were processed to obtain single-cell suspensions and were depleted of red blood cells by using commercial lysing buffer (Biolegend). Then, the percentage of human and mouse hematopoietic cells for each organ was determined by flow cytometry, using anti-human CD45 (clone HI30; Biolegend) and anti-mouse CD45 (clone 30-F11; Biolegend) antibodies.

We observed a high level of engraftment of human hematopoietic cells in both lymphoid tissues (40 to 80%) and peripheral tissues (10 to 40%) with the presence of fully differentiated human lymphocytes (T, B, NK, and NKT cells) and myeloid cells (monocytes, granulocytes, and dendritic cells) (data not shown). While the frequencies of these populations differed between experiments, all the human cell subsets were consistently observed in mice with transplanted HSCs. These data demonstrate that humanized NSG-A2 ([hu]NSG-A2) mice develop all cell components of a fully functional adaptive human immune system, in agreement with previous reports (9–11).
To test the susceptibility of huNSG-A2 mice to EBOV infection, we inoculated 1,000 focus-forming units (FFU) of EBOV (Ebola virus H.sapiens-tc/COD/1976/Yambuku-Mayinga) i.p. into mice with either low-level engraftment (20 to 40%) or high-level engraftment (>40%) of human hematopoietic cells in peripheral blood leukocytes. A mock group of mice with transplanted HSCs that received phosphate-buffered saline (PBS) was kept as a negative control. All EBOV-infected mice showed a marked weight loss starting around day 7 postinfection (Fig. 1A). By day 20, 50% of mice with low-level engraftment succumbed to EVD while the infection was lethal for 100% of mice with high-level engraftment. These results indicate that the severity of EBOV infection in huNSG-A2 mice was directly correlated with the level of engraftment of human hematopoietic cells.
The time of death reflected the incubation period and the course of EVD observed in humans (1).

A common characteristic of EVD in humans is high viremia and virus dissemination to peripheral organs, which is negatively correlated with disease outcome (1, 12). In mice with both low and high levels of engraftment, we observed infectious virus in blood at titers up to $10^5$ FFU/ml at the peak of disease (Fig. 1B). In addition, both groups of mice showed the presence of infectious virus in peripheral organs such as kidney, liver, lung, and brain (Fig. 1C). Interestingly, the viral titers were similar in both groups of mice, with liver and lung supporting high viral loads (Fig. 1C), which suggested that cells of mouse origin could support EBOV replication. This hypothesis was confirmed by immunofluorescence analysis of tissue sections using Alexa Fluor 488-conjugated anti-EBOV glycoprotein (GP) antibodies, a kind gift from Gary Kobinger, Public Health Agency of Canada, which revealed the presence of infected cells of mouse origin, such as liver hepatocytes (Fig. 1D). These findings strongly suggest that the higher susceptibility to lethal infection observed in mice with a high level of engraftment of human cells may be related to immunopathology rather than the presence of a higher number of human...
target cells for the virus, in agreement with findings in other EVD models such as nonhuman primates (NHPs) (13).

Next, we sought to evaluate the pathogenesis of EVD in huNSG-A2 mice. First we determined the serum levels of aspartate aminotransferase (AST) in EBOV-infected mice as an indication of cell damage (13). In mice with both low and high levels of HSC engraftment, we observed elevation of AST levels in serum over the course of disease, which mimicked findings in NHPs and human patients (1, 13–15) (Fig. 2A). Strikingly, assessment of gross pathology during necropsies indicated liver steatosis (fatty liver) in EBOV-infected mice (Fig. 2B), which was confirmed by visualization of small-droplet steatosis in tissue sections (Fig. 2D). Mild to moderate fatty liver is a common observation in postmortem examination of liver tissues from EBOV-infected NHPs and humans (16, 17) and to our knowledge has never been reproduced before in a mouse model of EVD. In one out of six necropsies performed, we also observed areas of focal hemorrhage and necrosis in the livers of EBOV-infected mice (Fig. 2B). Thus, our mouse model may also reproduce EBOV-associated bleeding disorders that are associated with EVD in a small percentage of human patients (1, 18). Necropsies also revealed clear signs of splenomegaly, a pathological finding previously reported in filovirus-infected NHPs (Fig. 2B) (19). The evaluation of histopathological features confirmed the necropsy findings that showed extensive lymphocytic infiltrates in spleen and lipid droplet deposits in the livers of EBOV-infected mice (Fig. 2C). Taken together, our results indicate that huNSG-A2 mice reproduce the pathological features of EVD in humans and NHPs, including liver damage, bleeding, and immunopathology.

To specifically determine the role of human hematopoietic cells in our system, we established two additional infection models. First, we utilized NSG-A2 mice without HSC transplantation, and second, we reconstituted the hematopoietic system in NSG-A2 mice with mouse bone marrow progenitor cells from C57BL/6 donor mice (moNSG-A2) (Fig. 3A). These moNSG-A2 mice developed a fully differentiated mouse hematopoietic system (data not shown). NSG-A2 mice without HSC transplantation showed only mild signs of disease until the third week postinfection, at which time they showed gradual weight loss until the time of death (Fig. 3A). These results suggested a lengthy disease similar to that of scid mice infected with Marburg virus (20). This hypothesis was further confirmed with the observation of long-term unresolved viremia in these mice, which was consistent with lack of virus clearance mechanisms (Fig. 3B). Serum levels of AST also increased gradually in these mice until the time of death (Fig. 3B).

Conversely, all moNSG-A2 mice survived EBOV infection, mimicking observations in wild-type inbred mice infected with nonadapted filoviruses (3). Interestingly, moNSG-A2 mice showed weight loss up to day 10 postinfection, which coincided with low levels of viremia and a transient elevation of AST (Fig. 3A and B). These results probably reflect the importance of innate immune responses for early control of EBOV replication, which are impaired in the nonhematopoietic compartment of moNSG-A2 mice (4, 21). The difference in EBOV virulence between moNSG-A2 mice and huNSG-A2 mice indicates the important role of human hematopoietic cells for pathogenesis in our model.

To the best of our knowledge, this study provides for the first time a small-animal model with a human hematopoietic system that recapitulates some of the main features of EVD pathogenesis, namely, viremia, cell and organ damage, and high lethality. We have also been able to reproduce these findings in huNSG-A2 mice infected intranasally (data not shown), suggesting susceptibility to nonadapted EBOV by several infection routes. Due to the functional HLA-A2-restricted CD8 T-cell responses observed in these mice in other viral infections (10, 11), we anticipate that our model will provide insight into not only the pathogenesis but also the correlates of immune protection against EBOV. Importantly,
we were able to observe signs of liver steatosis and hemorrhage, features of EVD in humans whose relevance in the disease is not well understood (1, 17, 18). We speculate that the presence of human macrophages, which are involved in both inflammation-associated fatty liver and disseminated intravascular coagulation (22, 23), may be responsible for these findings. Further optimization of the model via depletion of residual mouse macrophages (24) might help to further test this hypothesis. We expect that our model will serve to accelerate preclinical development of EBOV vaccines and antivirals and to determine correlates of immune protection against EVD in humans.

ACKNOWLEDGMENTS

We thank Ulla Müller, Gundula Plinitz-Stolze, and Rui Qiao for excellent technical support. We also thank Gary Kobinger for the monoclonal antibodies against EBOV GP.

This work was partially funded by a German Center of Infection Research (DZIF)-EBOCON grant to C. M.-F. and S.G. A.L. is a recipient of a predoctoral fellowship from the Leibniz Center of Infection. The Heinrich-Pette-Institute is financed by the German Federal Ministry of Health and the Freie und Hansestadt Hamburg.

None of the authors have any conflict of interest related with this study.

REFERENCES


